Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

• US 20060247311A1
• Filed: 04/07/2006
• Published: 11/02/2006
• Est. Priority Date: 03/21/2003
• Status: Abandoned Application

• Current Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Original Assignee: Dynogen Pharmaceuticals, Inc. (Edusa Pharmaceuticals, Inc.)
• Inventors: Thor, Karl Bruce, Landau, Steven B., Brettman, Lee R., Fraser, Matthew Oliver, Ricca, Daniel J., Burgard, Edward C.
• Application Number:
  US11/400,666
• Publication Number:
  US 20060247311A1
• Time in Patent Office: Days
• US Class Current: 514/551
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/00 Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/12 Antidiuretics, e.g. drugs for diabetes insipidus ADH A61P5/10

Abstract

A method is provided for using α₂δ subunit calcium channel modulators or other compounds that interact with the α₂δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α₂δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

Claims

1-43. -43. (canceled)

44. A method for treating overactive bladder, comprising administering to an individual in need thereof a therapeutically effective amount of a cyclic amino acid compound and an antimuscarinic, wherein said cyclic amino acid compound is a compound of formula I

45. The method of claim 44, wherein said cyclic amino acid compound is 1-(aminomethyl)-cyclohexane acetic acid or (1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid.

46. The method of claim 44, wherein said antimuscarinic is tolterodine.

47. A method for treating overactive bladder, comprising administering to an individual in need thereof a therapeutically effective amount of 1-(aminomethyl)-cyclohexane acetic acid and tolterodine.

48. A method for treating overactive bladder, comprising administering to an individual in need thereof a therapeutically effective amount of (1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid and tolterodine.